Company Shares of Vascular Biogenics Ltd. Drops by -16.53%

Vascular Biogenics Ltd. (NASDAQ:VBLT) has tumbled 16.53% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 26.63% in the last four weeks. The stocks have underperformed the S&P 500 by 15.53% during the past week but Vascular Biogenics Ltd. (NASDAQ:VBLT) it has outperformed the index in 4 weeks by 25.47%.

Vascular Biogenics Ltd. (NASDAQ:VBLT): The stock opened at $4.75 on Friday but the bulls could not build on the opening and the stock topped out at $4.75 for the day. The stock traded down to $4.00 during the day, due to lack of any buying support eventually closed down at $4.09 with a loss of -10.89% for the day. The stock had closed at $4.59 on the previous day. The total traded volume was 2,081,849 shares.

The company shares have dropped -34.24% from its 1 Year high price. On Sep 25, 2015, the shares registered one year high at $12.25 and the one year low was seen on Feb 1, 2016. The 50-Day Moving Average price is $3.83 and the 200 Day Moving Average price is recorded at $3.78.

Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, JMP Securities, maintains their rating on the shares of Vascular Biogenics Ltd. (NASDAQ:VBLT). JMP Securities has a Market Outperform rating on the shares. As per the latest research report, the brokerage house lowers the price target to $8 per share from a prior target of $16. The rating by the firm was issued on March 9, 2016. Institutional Investors own 1.34% of Vascular Biogenics Ltd. shares.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Companys program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.